Serious infections in patients with inflammatory bowel disease receiving anti‐tumor‐necrosis‐factor‐alpha therapy: An Australian and New Zealand experience

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Gastroenterology and Hepatology

• Publication date

  2010-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1440-1746.2010.06407.xPMID 21039834
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Review article: chronic viral infection in the anti‐tumour necrosis factor therapy era in inflammatory bowel disease

  2010cited by this paper
• European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.

  2009cited by this paper
• Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.

  2009cited by this paper
• Pneumocystis jiroveci (carinii) pneumonia following a second infusion of infliximab in a patient with ulcerative colitis.

  2009cited by this paper
• Meta‐analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis

  2009cited by this paper
• Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention

  2009cited by this paper
• Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients.

  2009cited by this paper
• Efficacy of adalimumab for the management of Inflammatory Bowel Disease in the Clinical Setting

  2009cited by this paper
• Use of infliximab in the prevention and delay of colectomy in severe steroid dependant and refractory ulcerative colitis.

  2008cited by this paper
• Herpes zoster in patients taking TNFalpha antagonists for chronic inflammatory joint disease.

  2008cited by this paper
• Risk factors for opportunistic infections in patients with inflammatory bowel disease.

  2008cited by this paper
• Tuberculosis notifications in Australia, 2006.

  2008cited by this paper
• Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis

  2007cited by this paper
• Pneumocystis jiroveci (carinii) Pneumonia After Infliximab Therapy: A Review of 84 Cases

  2007cited by this paper
• Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

  2007cited by this paper
• Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study

  2007cited by this paper
• Careful patient selection may improve response rates to infliximab in inflammatory bowel disease

  2007cited by this paper
• Anti-TNF Treatment in Inflammatory Bowel Disease

  2007cited by this paper
• Tuberculosis epidemiology in New Zealand: 1995-2004.

  2006cited by this paper
• High incidence of Crohn's disease in Canterbury, New Zealand: Results of an epidemiologic study

  2006cited by this paper
• Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

  2006cited by this paper
• Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.

  2006cited by this paper
• Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial

  2006cited by this paper
• Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.

  2006cited by this paper
• Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy.

  2006cited by this paper
• Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

  2005cited by this paper
• Infliximab for induction and maintenance therapy for ulcerative colitis.

  2005cited by this paper
• Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.

  2005cited by this paper
• Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.

  2005cited by this paper
• Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy.

  2004cited by this paper
• Optimizing anti-TNF treatment in inflammatory bowel disease.

  2004cited by this paper
• The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients.

  2004cited by this paper
• Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

  2003cited by this paper
• Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.

  2003cited by this paper
• Tuberculosis notifications in Australia, 2000.

  2002cited by this paper
• Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

  2002cited by this paper
• Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.

  2002cited by this paper
• Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial.

  2001cited by this paper
• Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

  2001cited by this paper
• Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis

  1994cited by this paper
• Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.

  1994cited by this paper
• Classification of inflammatory bowel disease.

  1989cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Pneumocystosis in a patient with rheumatoid arthritis on adalimumab therapy: a case-based review

  2023cites this paper
• Regional risk of tuberculosis and viral hepatitis with tumor necrosis factor-alpha inhibitor treatment: A systematic review

  2023cites this paper
• Systematic review of therapies for refractory ulcerative proctitis

  2023cites this paper
• Trends in the Epidemiology of Pneumocystis Pneumonia in Immunocompromised Patients without HIV Infection

  2023cites this paper
• Pathophysiological Concepts and Management of Pulmonary Manifestation of Pediatric Inflammatory Bowel Disease

  2022cites this paper
• Prophylaxis for Pneumocystis jirovecii pneumonia in patients with inflammatory bowel disease: A systematic review

  2022cites this paper
• Real-life burden of adverse reactions to biological therapy in inflammatory bowel disease: a single-centre prospective case series

  2021cites this paper
• Histoplasmosis Related to Immunosuppression in a Patient with Crohn’s Disease: A Diagnostic Challenge

  2021cites this paper
• Viral infections in inflammatory bowel disease: Tips and tricks for correct management

  2021cites this paper
• ¿Están recibiendo los pacientes con enfermedad inflamatoria intestinal una adecuada inmunización?

  2020cites this paper
• Emerging therapies with potential risks of medicine-related osteonecrosis of the jaw: a review of the literature

  2020cites this paper
• Beneficial effects of Ajuga chamaepitys (L.) Schreber subsp. chia (Schreber) and its iridoids on the colitis model: Histopathological and biochemical evidence.

  2020cites this paper
• Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review

  2020cites this paper
• Are patients with inflammatory bowel disease receiving adequate immunisation?

  2020cites this paper
• Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.

  2020cites this paper
• Nested case-control study on risk factors for opportunistic infections in patients with inflammatory bowel disease

  2019cites this paper
• Update upon the infection risk in patients receiving TNF alpha inhibitors

  2019cites this paper
• Primary varicella infection in children with systemic juvenile idiopathic arthritis under tocilizumab therapy

  2019cites this paper
• Vaccination rate and immunity of children and adolescents with inflammatory bowel disease or autoimmune hepatitis in Germany.

  2019cites this paper
• S2k‐Leitlinie zur Therapie der Psoriasis bei Kindern und Jugendlichen – Kurzfassung Teil 2

  2019cites this paper
• S2k guidelines for the treatment of psoriasis in children and adolescents – Short version part 2

  2019cites this paper
• Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care—An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition

  2018cites this paper
• Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis—An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition

  2018cites this paper
• A medicinal plant compound, capnoidine, prevents the onset of inflammation in a mouse model of colitis.

  2018cites this paper
• Pharmacological treatments and infectious diseases in pediatric inflammatory bowel disease

  2018cites this paper
• Review article: novel oral‐targeted therapies in inflammatory bowel disease

  2018cites this paper
• Zweiter österreichischer Konsensus zur sicheren Anwendung von anti-TNF-α-Antikörpern bei chronisch-entzündlichen Darmerkrankungen

  2018cites this paper
• A Synbiotic with Tumor Necrosis Factor-α Inhibitory Activity Ameliorates Experimental Jejunoileal Mucosal Injury

  2018cites this paper
• Cytomegalovirus, inflammatory bowel disease, and anti-TNFα

  2017cites this paper
• Low Risk of Pneumonia From Pneumocystis jirovecii Infection in Patients With Inflammatory Bowel Disease Receiving Immune Suppression

  2017cites this paper
• Invasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF‐α) inhibitors

  2017cites this paper
• [Pneumocystis jiroveci pneumonia following infliximab therapy in patient with Crohn's disease].

  2017cites this paper
• Management and Prevention of Infectious Diseases in IBD Patients

  2017cites this paper
• Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders.

  2017cites this paper
• Exploring low molecular weight molecules produced by hookworms (Ancylostoma caninum) and their use as anti-inflammatory agents

  2017cites this paper
• Pneumocystis jirovecii Pneumonia in Pediatric Inflammatory Bowel Disease: A Case Report and Literature Review

  2017cites this paper
• Adalimumab: Another Medication Related to Osteonecrosis of the Jaws?

  2016cites this paper
• Phase III Placebo-Controlled, Randomized Clinical Trial With Synthetic Crohn's Disease Patients to Evaluate Treatment Response

  2016cites this paper
• NASPGHAN Clinical Report: Surveillance, Diagnosis, and Prevention of Infectious Diseases in Pediatric Patients With Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-α Inhibitors.

  2016cites this paper
• Effectiveness of a systematic vaccination program in patients with autoimmune inflammatory disease treated with anti-TNF alpha drugs

  2016cites this paper
• NADPH oxidases and inflammatory bowel disease.

  2015cites this paper
• Nanomedicine and drug delivery strategies for treatment of inflammatory bowel disease.

  2015cites this paper
• Early investigational TNF receptor antagonists for the treatment of ulcerative colitis

  2015cites this paper
• Mongersen , an Oral SMAD 7 Antisense Oligonucleotide , and Crohn ’ s Disease

  2015cites this paper
• Increased risk of varicella zoster virus infection in inflammatory bowel disease in an Asian population: a nationwide population‐based cohort study

  2015cites this paper
• Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease.

  2015cites this paper
• Integrins and adhesion molecules as targets to treat inflammatory bowel disease.

  2015cites this paper
• Vaccination in inflammatory bowel disease patients: attitudes, knowledge, and uptake.

  2015cites this paper
• Short-term effect and adverse events of adalimumab versus placebo in inducing remission for moderate-to-severe ulcerative colitis: a meta-analysis.

  2015cites this paper
• Infection risk associated with anti-TNF-α agents: a review

  2015cites this paper
• Pneumocystis Pneumonia in Inflammatory Bowel Disease: The Costs of Immunosuppression

  2015cites this paper
• Latent tuberculosis screening tests and active tuberculosis infection rates in Turkish inflammatory bowel disease patients under anti-tumor necrosis factor therapy

  2015cites this paper
• Adalimumab for Crohn's disease in New Zealand--a prospective multicentre experience.

  2014cites this paper
• Osteonecrosis of the jaw in a Crohn’s disease patient following a course of Bisphosphonate and Adalimumab therapy: a case report

  2014cites this paper
• Screening prior to biological therapy in Crohn's disease: adherence to guidelines and prevalence of infections. Results from a multicentre retrospective study.

  2014cites this paper
• Risk of infections of biological therapies with accent on inflammatory bowel disease.

  2014cites this paper
• TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future.

  2014cites this paper
• What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails?

  2014cites this paper
• Preventing infective complications in inflammatory bowel disease.

  2014cites this paper
• Guías de recomendaciones de prevención de infecciones en pacientes que reciben modificadores de la respuesta biológica

  2014cites this paper
• [Pneumocystis jiroveci pneumonia in a Crohn's disease patient treated with adalimumab].

  2014cites this paper
• Pneumocystis jirovecii Pneumonia in Patients Receiving Tumor-Necrosis-Factor-Inhibitor Therapy: Implications for Chemoprophylaxis

  2014cites this paper
• Infliximab Therapy for Pediatric Crohn Disease and Ulcerative Colitis

  2013cites this paper
• Implementing guidelines on the prevention of opportunistic infections in inflammatory bowel disease.

  2013cites this paper
• Pneumocystis Jiroveci Pneumonia in Patients with Inflammatory Bowel Disease: A Survey of Prophylaxis Patterns Among Gastroenterology Providers

  2013cites this paper
• From the Medical Board of the National Psoriasis Foundation: Vaccination in adult patients on systemic therapy for psoriasis.

  2013cites this paper
• Treatment of inflammatory bowel disease by chemokine receptor-targeted leukapheresis.

  2013cites this paper
• Increased Risk of Pneumocystis Jiroveci Pneumonia Among Patients with Inflammatory Bowel Disease

  2013cites this paper
• Systematic review: macrophage activation syndrome in inflammatory bowel disease

  2013cites this paper
• Incidence and characteristics of the 2009 influenza (H1N1) infections in inflammatory bowel disease patients.

  2013cites this paper
• Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature.

  2013cites this paper
• Efficacy and safety of interferon-gamma-targeted therapy in Crohn's disease: a systematic review and meta-analysis of randomized controlled trials.

  2013cites this paper
• Pneumocystis Jiroveci Pneumonia in Inflammatory Bowel Disease: When Should Prophylaxis be Considered?

  2013cites this paper
• Contribution of epithelial innate immunity to systemic protection afforded by prolyl hydroxylase inhibition in murine colitis

  2013cites this paper
• Cytomegalovirus pneumonia in patients with inflammatory bowel disease: a systematic review.

  2012cites this paper
• Ulcerative colitis.

  2012cites this paper
• Varicella zoster virus infection in inflammatory bowel disease

  2012cites this paper
• Management and Prevention of Infectious Diseases in Inflammatory Bowel Disease Patients

  2012cites this paper
• Mucormycosis of the intestine: a rare complication in Crohn's disease.

  2012cites this paper
• Sepsis, the Liver and the Gut

  2012cites this paper
• Pneumocystosis in a patient with Crohn's disease treated with combination therapy with adalimumab.

  2012cites this paper
• Opportunistic infections in paediatric inflammatory bowel disease patients

  2011cites this paper
• Biologics in Paediatric Crohn's Disease

  2011cites this paper
• Anti-tumour-necrosis-factor-alpha agents and the heart: beyond left ventricular systolic dysfunction?

  2011cites this paper
• Pneumocystis jirovecii pneumonia in non-HIV-infected patients: new risks and diagnostic tools

  2011cites this paper